Latest Fairmount Funds Management LLC Stock Portfolio
Fairmount Funds Management LLC Performance:
2025 Q4: 50.54%YTD: 70.58%2024: 16.09%
Performance for 2025 Q4 is 50.54%, and YTD is 70.58%, and 2024 is 16.09%.
About Fairmount Funds Management LLC and 13F Hedge Fund Stock Holdings
On 2026-02-17, the fund reported it's updated stock portfolio. In the 13F Holdings report, Fairmount Funds Management LLC reported an equity portfolio of $1.3 Billions as of 31 Dec, 2025.
The top stock holdings of Fairmount Funds Management LLC are COGT, , AGLE. The fund has invested 24.3% of it's portfolio in COGENT BIOSCIENCES INC and 11.8% of portfolio in APOGEE THERAPEUTICS INC.
The fund managers got completely rid off AXSOME THERAPEUTICS INC (AXSM), SCHOLAR ROCK HLDG CORP (SRRK) and ABIVAX SA stocks. They significantly reduced their stock positions in DIANTHUS THERAPEUTICS INC. The fund showed a lot of confidence in some stocks as they added substantially to CRESCENT BIOPHARMA INC., JADE BIOSCIENCES INC (AVTE) and INHIBIKASE THERAPEUTICS INC (IKT).
The top stock holdings of Fairmount Funds Management LLC are COGT, , AGLE. The fund has invested 24.3% of it's portfolio in COGENT BIOSCIENCES INC and 11.8% of portfolio in APOGEE THERAPEUTICS INC.
The fund managers got completely rid off AXSOME THERAPEUTICS INC (AXSM), SCHOLAR ROCK HLDG CORP (SRRK) and ABIVAX SA stocks. They significantly reduced their stock positions in DIANTHUS THERAPEUTICS INC. The fund showed a lot of confidence in some stocks as they added substantially to CRESCENT BIOPHARMA INC., JADE BIOSCIENCES INC (AVTE) and INHIBIKASE THERAPEUTICS INC (IKT).
Fairmount Funds Management LLC Annual Return Estimates Vs S&P 500
Our best estimate is that Fairmount Funds Management LLC made a return of 50.54% in the last quarter. In trailing 12 months, it's portfolio return was 70.58%.
- Performance
- S&P 500
New Buys
Additions
| Ticker | % Inc. |
|---|---|
| crescent biopharma inc. | 97.99 |
| jade biosciences inc | 41.4 |
| inhibikase therapeutics inc | 40.82 |
| zenas biopharma inc | 16.71 |
| viridian therapeutics inc | 13.14 |
Additions to existing portfolio by Fairmount Funds Management LLC
Reductions
| Ticker | % Reduced |
|---|---|
| dianthus therapeutics inc | -35.38 |
| kiniksa pharmaceuticals intl | -25.56 |
Fairmount Funds Management LLC reduced stake in above stock
Sold off
| Ticker | $ Sold |
|---|---|
| astria therapeutics inc | -25,874,100 |
| scholar rock hldg corp | -67,926,900 |
| axsome therapeutics inc | -99,003,100 |
| abivax sa | -60,570,500 |
Fairmount Funds Management LLC got rid off the above stocks
Sector Distribution
Fairmount Funds Management LLC has about 55.9% of it's holdings in Healthcare sector.
- Healthcare
- Others
| Sector | % |
|---|---|
| Healthcare | 55.9 |
| Others | 44.1 |
Market Cap. Distribution
Fairmount Funds Management LLC has about 0% of it's portfolio invested in the large-cap and mega-cap stocks.
- MID-CAP
- UNALLOCATED
- SMALL-CAP
- MICRO-CAP
| Category | % |
|---|---|
| MID-CAP | 49.2 |
| UNALLOCATED | 44.1 |
| SMALL-CAP | 5.3 |
| MICRO-CAP | 1.3 |
Stocks belong to which Index?
About 44.5% of the stocks held by Fairmount Funds Management LLC either belong to S&P 500 or RUSSELL 2000 index.
- Others
- RUSSELL 2000
| Index | % |
|---|---|
| Others | 55.5 |
| RUSSELL 2000 | 44.5 |
Fairmount Funds Management LLC Holdings Map
This heatmap illustrates the top 50 positions within the fund's portfolio.
Current Stock Holdings of Fairmount Funds Management LLC
Fairmount Funds Management LLC has 13 stocks in it's portfolio. About 92% of the portfolio is in top 10 stocks. proved to be the most loss making stock for the portfolio. COGT was the most profitable stock for Fairmount Funds Management LLC last quarter.
Last Reported on: 17 Feb, 2026| Ticker | Namesorted ascending | % Portfolio | Shares Held | $ Value | Type | % Change | Options | |
|---|---|---|---|---|---|---|---|---|
| AGLE | spyre therapeutics inc | 10.02 | 4,018,100 | 131,633,000 | unchanged | 0.00 | ||
| ATXS | astria therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| AVTE | jade biosciences inc | 5.35 | 4,553,490 | 70,260,400 | added | 41.4 | ||
| AXSM | axsome therapeutics inc | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| COGT | cogent biosciences inc | 24.34 | 9,003,420 | 319,801,000 | unchanged | 0.00 | ||
| IKT | inhibikase therapeutics inc | 1.35 | 8,625,000 | 17,681,200 | added | 40.82 | ||
| NUVL | nuvalent inc | 5.57 | 727,563 | 73,185,600 | unchanged | 0.00 | ||
| SRRK | scholar rock hldg corp | 0.00 | 0.00 | 0.00 | sold off | -100 | ||
| VRDN | viridian therapeutics inc | 9.27 | 3,914,460 | 121,818,000 | added | 13.14 | ||
| apogee therapeutics inc | 11.77 | 2,048,650 | 154,632,000 | unchanged | 0.00 | |||
| oruka therapeutics inc | 8.55 | 3,705,260 | 112,306,000 | unchanged | 0.00 | |||
| dianthus therapeutics inc | 6.70 | 2,137,190 | 88,073,600 | reduced | -35.38 | |||
| zenas biopharma inc | 6.11 | 2,209,020 | 80,209,700 | added | 16.71 | |||
| enliven therapeutics inc | 4.35 | 3,711,440 | 57,156,200 | unchanged | 0.00 | |||
| kiniksa pharmaceuticals intl | 4.14 | 1,319,690 | 54,437,100 | reduced | -25.56 | |||
| crescent biopharma inc. | 2.48 | 2,747,870 | 32,589,700 | added | 97.99 | |||
| abivax sa | 0.00 | 0.00 | 0.00 | sold off | -100 | |||